Sirolimus as a second-line treatment for Graves' orbitopathy

Area of Science:

• Ophthalmology
• Endocrinology
• Immunology

Background:

• Graves' orbitopathy (GO) is an autoimmune condition affecting the eye tissues.
• Current second-line treatments have limitations, necessitating alternative therapeutic options.
• Sirolimus has shown potential benefits in preliminary studies for GO management.

Purpose of the Study:

• To compare the efficacy of sirolimus versus methylprednisolone as a second-line treatment for moderate-to-severe active Graves' orbitopathy.
• To evaluate the overall GO outcome, quality of life, proptosis, clinical activity score, eye ductions, and eyelid aperture at 24 weeks.

Main Methods:

• An observational, single-center study compared sirolimus (oral) with methylprednisolone (intravenous) in 30 GO patients.
• Patients received either sirolimus (2 mg day 1, then 0.5 mg/day for 12 weeks) or methylprednisolone (500 mg/week for 6 weeks, then 250 mg/week for 6 weeks).
• Outcomes were assessed at 24 weeks, including a composite GO response, GO-Quality of Life (GO-QoL) score, proptosis, clinical activity score (CAS), eye ductions, and eyelid aperture.

Main Results:

• Sirolimus treatment resulted in a significantly higher proportion of GO responders (86.6%) compared to methylprednisolone (26.6%) at 24 weeks (OR: 17.8, P=0.0026).
• The sirolimus group showed greater improvements in GO-QoL scores, proptosis, and CAS.
• No serious adverse events were reported in either treatment group, indicating a favorable safety profile for sirolimus in this context.

Conclusions:

• Sirolimus appears to be an effective second-line therapy for moderate-to-severe active Graves' orbitopathy.
• The drug demonstrated significant improvements in clinical outcomes and patient-reported quality of life.
• Further randomized controlled trials are recommended to validate these promising findings and establish sirolimus as a standard treatment option.